269 related articles for article (PubMed ID: 10444280)
1. Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.
Scharrer I; Bray GL; Neutzling O
Haemophilia; 1999 May; 5(3):145-54. PubMed ID: 10444280
[TBL] [Abstract][Full Text] [Related]
2. Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A.
Mauser-Bunschoten EP; van der Bom JG; Bongers M; Twijnstra M; Roosendaal G; Fischer K; van den Berg HM
Haemophilia; 2001 Jul; 7(4):364-8. PubMed ID: 11442640
[TBL] [Abstract][Full Text] [Related]
3. Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates.
Zanon E; Zerbinati P; Girolami B; Bertomoro A; Girolami A
Blood Coagul Fibrinolysis; 1999 Apr; 10(3):117-20. PubMed ID: 10357004
[TBL] [Abstract][Full Text] [Related]
4. Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.
Volkers P; Hanschmann KM; Calvez T; Chambost H; Collins PW; Demiguel V; Hart DP; Hay CRM; Goudemand J; Ljung R; Palmer BP; Santagostino E; van Hardeveld EM; van den Berg M; Keller-Stanislawski B
Haemophilia; 2019 May; 25(3):398-407. PubMed ID: 31066174
[TBL] [Abstract][Full Text] [Related]
5. Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debate?
Berntorp E
Hamostaseologie; 2017 Jan; 37(1):53-57. PubMed ID: 27878207
[TBL] [Abstract][Full Text] [Related]
6. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development.
Ettingshausen CE; Kreuz W
Haemophilia; 2006 Dec; 12 Suppl 6():102-6. PubMed ID: 17123402
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products.
Rota M; Cortesi PA; Steinitz-Trost KN; Reininger AJ; Gringeri A; Mantovani LG
Blood Coagul Fibrinolysis; 2017 Dec; 28(8):627-637. PubMed ID: 28678027
[TBL] [Abstract][Full Text] [Related]
8. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
Hassan S; Cannavò A; Gouw SC; Rosendaal FR; van der Bom JG
J Thromb Haemost; 2018 Jun; 16(6):1055-1068. PubMed ID: 29665204
[TBL] [Abstract][Full Text] [Related]
9. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review.
Franchini M; Tagliaferri A; Mengoli C; Cruciani M
Crit Rev Oncol Hematol; 2012 Jan; 81(1):82-93. PubMed ID: 21277222
[TBL] [Abstract][Full Text] [Related]
10. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
Shirahata A; Fukutake K; Higasa S; Mimaya J; Oka T; Shima M; Takamatsu J; Taki M; Taneichi M; Yoshioka A;
Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
[TBL] [Abstract][Full Text] [Related]
11. Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study.
Liesner RJ; Abraham A; Altisent C; Belletrutti MJ; Carcao M; Carvalho M; Chambost H; Chan AKC; Dubey L; Ducore J; Gattens M; Gresele P; Gruel Y; Guillet B; Jimenez-Yuste V; Kitanovski L; Klukowska A; Lohade S; Mancuso ME; Oldenburg J; Pavlova A; Pollio B; Sigaud M; Vdovin V; Vilchevska K; Wu JKM; Jansen M; Belyanskaya L; Walter O; Knaub S; Neufeld EJ
Thromb Haemost; 2021 Nov; 121(11):1400-1408. PubMed ID: 33581698
[TBL] [Abstract][Full Text] [Related]
12. Previously untreated patients and recombinant factor VIII concentrate studies.
Pasi KJ
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S29-32. PubMed ID: 9351534
[TBL] [Abstract][Full Text] [Related]
13. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
Peyvandi F; Cannavò A; Garagiola I; Palla R; Mannucci PM; Rosendaal FR;
J Thromb Haemost; 2018 Jan; 16(1):39-43. PubMed ID: 29080391
[TBL] [Abstract][Full Text] [Related]
14. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.
Gouw SC; van der Bom JG; Auerswald G; Ettinghausen CE; Tedgård U; van den Berg HM
Blood; 2007 Jun; 109(11):4693-7. PubMed ID: 17218379
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors incidence rate in Czech previously untreated patients with haemophilia A has not increased since introduction of recombinant factor VIII treatment in 2003.
Blatny J; Komrska V; Blazek B; Penka M; Ovesna P;
Blood Coagul Fibrinolysis; 2015 Sep; 26(6):673-8. PubMed ID: 25886834
[TBL] [Abstract][Full Text] [Related]
16. Incidence of inhibitors in haemophiliacs. A review of the literature.
Scharrer I; Neutzling O
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):753-8. PubMed ID: 8292725
[TBL] [Abstract][Full Text] [Related]
17. Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.
Calvez T; Chambost H; d'Oiron R; Dalibard V; Demiguel V; Doncarli A; Gruel Y; Huguenin Y; Lutz P; Rothschild C; Vinciguerra C; Goudemand J;
Haematologica; 2018 Jan; 103(1):179-189. PubMed ID: 29025913
[TBL] [Abstract][Full Text] [Related]
18. Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors.
van den Berg HM
Haemophilia; 2014 May; 20 Suppl 4():76-9. PubMed ID: 24762280
[TBL] [Abstract][Full Text] [Related]
19. Inhibitor development in non-severe haemophilia across Europe.
Fischer K; Iorio A; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Gilman EA; Hollingsworth R; Makris M;
Thromb Haemost; 2015 Oct; 114(4):670-5. PubMed ID: 26293381
[TBL] [Abstract][Full Text] [Related]
20. The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison.
Hay CRM; Palmer BP; Chalmers EA; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Collins PW
Haemophilia; 2015 Mar; 21(2):219-226. PubMed ID: 25382829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
